Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO) announced that the first participant has been dosed in the phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A patients. As per the terms of the collaboration deal, Sangamo has now earned a $30 million milestone payment.
Pfizer is now operationally and financially responsible for research, development, manufacturing and commercialization activities for giroctocogene fitelparvovec following the transfer of the Investigational New Drug from Sangamo to Pfizer in December 2019.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.